Tran H, Chen K, Shumack S
Department of Dermatology, St George Hospital, University of NSW, Sydney, Australia.
Br J Dermatol. 2003 Nov;149 Suppl 66:37-9. doi: 10.1046/j.0366-077x.2003.05629.x.
Imiquimod is being investigated as a therapeutic option for the management of actinic keratosis. Three recent clinical trials have demonstrated a reasonable efficacy rate and high safety profile. 'Cycle' therapy may improve the safety profile while maintaining efficacy. 'Field' treatment with imiquimod may uncover and treat 'subclinical' actinic keratoses, which in turn may potentially result in fewer recurrences. Longer follow-up studies are required to investigate this possibility.
咪喹莫特正作为光化性角化病治疗的一种选择进行研究。最近的三项临床试验已证明其有效率合理且安全性高。“循环”疗法可能在保持疗效的同时改善安全性。用咪喹莫特进行“区域”治疗可能会发现并治疗“亚临床”光化性角化病，这反过来可能会减少复发。需要进行更长时间的随访研究来调查这种可能性。
